Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bevin McGettigan-Croce"'
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Autor:
Vijay G. Bhoj, Lucy Li, Kalpana Parvathaneni, Zheng Zhang, Stephen Kacir, Dimitrios Arhontoulis, Kenneth Zhou, Bevin McGettigan-Croce, Selene Nunez-Cruz, Gayathri Gulendran, Alina C. Boesteanu, Laura Johnson, Michael D. Feldman, Enrico Radaelli, Keith Mansfield, MacLean Nasrallah, Rebecca S. Goydel, Haiyong Peng, Christoph Rader, Michael C. Milone, Don L. Siegel
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 387-398 (2021)
Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modifi
Externí odkaz:
https://doaj.org/article/21295495ac0b4d158ff8bf09829bb9f3
Autor:
Yibo Yin, Alina C. Boesteanu, Zev A. Binder, Chong Xu, Reiss A. Reid, Jesse L. Rodriguez, Danielle R. Cook, Radhika Thokala, Kristin Blouch, Bevin McGettigan-Croce, Logan Zhang, Christoph Konradt, Alexandria P. Cogdill, M. Kazim Panjwani, Shuguang Jiang, Denis Migliorini, Nadia Dahmane, Avery D. Posey, Jr., Carl H. June, Nicola J. Mason, Zhiguo Lin, Donald M. O’Rourke, Laura A. Johnson
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 20-38 (2018)
We generated two humanized interleukin-13 receptor α2 (IL-13Rα2) chimeric antigen receptors (CARs), Hu07BBz and Hu08BBz, that recognized human IL-13Rα2, but not IL-13Rα1. Hu08BBz also recognized canine IL-13Rα2. Both of these CAR T cell construc
Externí odkaz:
https://doaj.org/article/c4f59e6339ce4efa84b3ecf00abab181
Autor:
Mohammad Haris, Puneet Bagga, Hari Hariharan, Bevin McGettigan-Croce, Laura A. Johnson, Ravinder Reddy
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-7 (2017)
Abstract While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a var
Externí odkaz:
https://doaj.org/article/6942e16953dc47e18f62e5efe994ab64
Autor:
Mireia Uribe-Herranz, Silvia Beghi, Marco Ruella, Kalpana Parvathaneni, Silvano Salaris, Nektarios Kostopoulos, Subin S. George, Stefano Pierini, Elisavet Krimitza, Francesca Costabile, Guido Ghilardi, Kimberly V. Amelsberg, Yong Gu Lee, Raymone Pajarillo, Caroline Markmann, Bevin McGettigan-Croce, Divyansh Agarwal, Noelle Frey, Simon F. Lacey, John Scholler, Khatuna Gabunia, Gary Wu, Elise Chong, David L. Porter, Carl H. June, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene
Publikováno v:
Molecular Therapy. 31:686-700
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f452ab38962928b51e549d95a9be6f55
https://doi.org/10.1016/j.ymthe.2023.01.012
https://doi.org/10.1016/j.ymthe.2023.01.012
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Autor:
Selene Nunez-Cruz, Michael Feldman, Kenneth Zhou, Christoph Rader, Haiyong Peng, Stephen Kacir, Keith Mansfield, Alina C. Boesteanu, Zheng Zhang, Enrico Radaelli, MacLean Nasrallah, Bevin McGettigan-Croce, Rebecca S. Goydel, Vijay Bhoj, Don L. Siegel, Michael C. Milone, Kalpana Parvathaneni, Gayathri Gulendran, Dimitrios Arhontoulis, Lucy Z. Li, Laura A. Johnson
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 387-398 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 387-398 (2021)
Metastatic medullary thyroid cancer (MTC) is a rare but often aggressive thyroid malignancy with a 5-year survival rate of less than 40% and few effective therapeutic options. Adoptive T cell immunotherapy using chimeric antigen receptor (CAR)-modifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136615ee16ed55eb834ffa1e9b74f952
https://pubmed.ncbi.nlm.nih.gov/33614919
https://pubmed.ncbi.nlm.nih.gov/33614919
Autor:
Hari Hariharan, Ravinder Reddy, Mohammad Haris, Laura A. Johnson, Puneet Bagga, Bevin McGettigan-Croce
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-7 (2017)
Journal of Translational Medicine
Journal of Translational Medicine
While many decades of scientific research studies have gone into harnessing the power of the immune system to fight cancer, only recently have cancer immunotherapeutic approaches begun to show robust clinical responses in patients with a variety of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd74a372cb02e978f6f69293505cb80
http://link.springer.com/article/10.1186/s12967-017-1240-6
http://link.springer.com/article/10.1186/s12967-017-1240-6
Autor:
Laura A. Johnson, Carl H. June, Chong Xu, Yibo Yin, Bevin McGettigan-Croce, Nicola J. Mason, Danielle R. Cook, Kristin Blouch, Zhiguo Lin, Alina C. Boesteanu, Avery D. Posey
Publikováno v:
Journal of Clinical Oncology. 35:152-152
152 Background: Glioblastoma (GBM) is a deadly cancer, with a 5-year survival rate of less than 10%. T cells can be redirected to kill cancer cells using chimeric antigen receptors (CAR), a promising method to treat solid tumors. IL13Rα2 is expresse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17b39e3f6fa84619b147c682e5605e27
https://doi.org/10.1200/jco.2017.35.7_suppl.152
https://doi.org/10.1200/jco.2017.35.7_suppl.152